Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma

STATEMENT OF NEED

Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche into circulation. Stem cell mobilization strategies differ in terms of stem cell yields, safety considerations, and resource utilization, and mobilization failure remains a concern in spite of the incorporation of novel agents into conventional methods. Therefore, it is crucial that clinicians apply interdisciplinary strategies to mitigate poor mobilization and optimize ASCT outcomes (Wei & Wei, 2023). In this activity, Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center and Assistant Professor of Clinical Medicine at Weill Cornell Medical College, will share insights into cracking the code to successful stem cell mobilization in multiple myeloma.

TARGET AUDIENCE

Hematologists, medical oncologists, advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with multiple myeloma.